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Human metapneumovirus epidemiological
and evolutionary patterns in Coastal Kenya,
2007-11
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and D. James Nokes1,3*
Abstract
Background: Human metapneumovirus (HMPV) is an important global cause of severe acute respiratory infections
in young children and the elderly. The epidemiology of HMPV in sub-Saharan Africa is poorly described and factors
that allow its recurrent epidemics in communities not understood.
Methods: We undertook paediatric inpatient surveillance for HMPV in Kilifi County Hospital (KCH) of Coastal Kenya
between 2007 and 2011. Nasopharyngeal samples collected from children aged 1 day–59 months admitted with
severe or very severe pneumonia, were tested for HMPV using real-time polymerase chain reaction (RT-PCR). Partial
nucleotide sequences of the attachment (G) and fusion (F) surface proteins of positive samples were determined
and phylogenetically analyzed.
Results: HMPV was detected in 4.8 % (160/3320) of children [73.8 % (118/160) of these less than one year of age],
ranging between 2.9 and 8.8 % each year over the 5 years of study. HMPV infections were seasonal in occurrence,
with cases predominant in the months of November through April. These months frequently coincided with low
rainfall, high temperature and low relative humidity in the location. Phylogenetic analysis of partial F and G
sequences revealed three subgroups of HMPV, A2 (74 %, 91/123), B1 (3.2 %, 4/123) and B2 (22.8 %, 28/123) in
circulation, with subgroup A2 predominant in majority of the epidemic seasons. Comparison of G sequences (local
and global) provided a greater phylogenetic resolution over comparison of F sequences and indicated presence of
probable multiple G antigenic variants within the subgroups due to differences in amino acid sequence, encoded
protein length and glycosylation patterns.
Conclusion: The present study reveals HMPV is an important seasonal contributor to respiratory disease
hospitalization in coastal Kenya, with an evolutionary pattern closely relating to that of respiratory syncytial virus.
Keywords: Human metapneumovirus, Genetic diversity, Respiratory virus, Kenya, Kilifi
Background
Human metapneumovirus (HMPV), a close relative of
respiratory syncytial virus (RSV), is a recognized major
human pathogen that causes epidemics of respiratory
tract illnesses in persons of all ages worldwide [1, 2].
Discovered in 2001 [1], HMPV was probably circulating
for at least 50 years prior to this date [1]. Infection with
HMPV may manifest as upper or lower tract respiratory
illness, similar to that observed with RSV disease al-
though HMPV has a considerably lower individual dis-
ease risk and population burden than RSV [3, 4].
A member of the Paramyxoviridae family of viruses,
HMPV genome is a negative-sense single-stranded RNA
molecule, 13.3 Kb long, encoding eight proteins [5].
Three surface proteins F (fusion), G (attachment glyco-
protein) and SH (small hydrophobic) are encoded within
the HMPV genome [6] and F and G nucleotide se-
quences have been largely used to study HMPV genetic
variation [7]. Whilst the G gene shows higher sequence
* Correspondence: BOwor@kemri-wellcome.org; JNokes@kemri-wellcome.org
1Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research
Programme, Kilifi, KEMRI Centre for Geographic Medicine Research - Coast,
Kilifi, Kenya
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Owor et al. BMC Infectious Diseases  (2016) 16:301 
DOI 10.1186/s12879-016-1605-0
and amino acid diversity [8–11], only the F protein is
confirmed to be immunogenic and protective [6, 12].
In the northern hemisphere peak HMPV disease occur-
rence is typically in winter and spring months of January
to May [13–15], while in the southern hemisphere peak
prevalence is in the spring period of August to September
[16]. In Kenya, peak HMPV prevalence has been re-
corded in June-July in the west and November-December
in refugee camps in the northeast and northwest of the
country [17, 18].
Worldwide, HMPV prevalence in hospital inpatient or
community studies, in children or elderly adults, varies
widely from as low as 1.7 % to as high as 17 %, with gen-
erally higher prevalence in outpatients compared to in-
patients and, also, more in children younger than 5 years
compared to older age groups [7, 13, 14, 16, 19–26].
Studies in Kenya report HMPV prevalence between 3
and 6 % in acute respiratory infection cases in inpatient
populations [17, 27–29], and 7 to 8.6 % in outpatient
[17, 30] but none have provided information on virus
genetic characteristics and underlying evolutionary changes
over successive epidemic seasons.
HMPV has been divided into two serologically distinct
groups, A and B [1, 31]. Group A generally dominates
over group B [7, 24–26, 32] and has been reported to
cause more severe disease than group B [33]. The two
groups are further subdivided into subgroups A1, A2, B1
and B2 based on genetic differences in the surface pro-
teins F and G but these do not show clear antigenic dif-
ferences at least in neutralization assays using anti-sera
raised in ferrets [8]. The A2 subgroup is the most genet-
ically heterogeneous of the four subgroups and some
studies have suggested its further sub-division into A2a
and A2b sub-lineages based on sequence data [34, 35].
Based on the F gene, HMPV groups A and B have 84–
86 % homology at nucleotide level and 94–97 % at amino
acid level whilst within subgroup similarity is 94–96 % at
nucleotide and 97–99 % at amino acid levels [8]. In com-
parison, the more diverse G protein shows only 50–57 %
and 30–37 % similarity for nucleotide and amino acid se-
quences, respectively, between the two groups A and B
[8]. Variants from both groups, and sometimes from mul-
tiple subgroups within the groups, can co-circulate in the
same epidemic season [8, 12, 14, 35, 36].
Candidate vaccines targeting the G protein and a sub-
unit vaccine of the F protein have shown promising re-
sults although, to date, none is licensed [37–40]. We set
out to understand the genetic diversity in the F and G
genes in circulating strains in coastal Kenya in relation
to seasonal introductions of the virus, to contribute in-
formation that may be important for vaccine develop-
ment and virus infection control. We describe the
molecular epidemiology of HMPV in child admissions at
a coastal county hospital of Kenya, over a 5-year period,
building on previous work in the hospital [27] in order
to elucidate prevalence, circulating strains and genetic
diversity in the most at risk paediatric population, con-
tributing information on HMPV persistence and
transmission.
Methods
Study population and sample collection
Study participants were identified through continuous
surveillance of pneumonia admissions to the paediatric
wards of Kilifi County Hospital (KCH) over a 5-year
period between January 2007 and December 2011. KCH
is located in coastal Kenya, 60 km north of Mombasa
and is the main hospital that serves the residents of Kilifi
County. The hospital handles 4000 to 4500 paediatric
admissions annually and around 30 % of the under 5 year
olds have an admission diagnosis of lower respiratory
tract infection (LRTI) based on WHO definitions of se-
vere and very severe pneumonia [41]. Hospital admis-
sions can be further stratified according to residency
within the Kilifi Health and Demographic Surveillance
System, KHDSS [42]. Each year this coastal location ex-
periences two rainy seasons: long rains between April
and July and short rains between October and Decem-
ber. Further details of the location and ongoing surveil-
lance have previously been described [27, 28, 43, 44].
Children were eligible for the current study if at ad-
mission they were aged 1 day to 59 months with syn-
dromic severe or very severe pneumonia, i.e. cough or
difficulty in breathing plus any one or more of the fol-
lowing: lower chest wall indrawing (severe pneumonia),
oxygen saturation of less than 90 % (finger tip pulse
oximetry), inability to drink or breast feed, prostrate or
unconscious (very severe pneumonia) [27]. Following
written informed consent from the parent or guardian, a
nasopharyngeal flocked swab, nasal wash or combination
of nasopharyngeal swab and oropharyngeal swab was
collected from each child, placed in 3 ml viral transport
medium, and stored at −80 °C prior to laboratory
screening. The Kenya National Ethical Review Commit-
tee approved the study protocols.
Diagnostic real-time polymerase chain reaction (RT-PCR)
RNA was extracted from either 200 or 140 μl of naso-
pharyngeal samples using MagNA Pure LC32 automated
total nucleic acid extractor (Roche Applied Science,
Mannheim, Germany) or QIAamp Viral RNA minikit
(Qiagen, Valencia, CA, USA), respectively, according to
the manufacturer’s instructions, for virus screening and
sequencing respectively. Virus detection was done using
real-time PCR using a TaqMan probe based system as
described by Hammitt et al., [28] in a multiplex PCR
assay run on the ABI 7500 (version 2.5, Applied Biosys-
tems, Foster City, California, USA). Samples with a cycle
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threshold (Ct) values of less than 35.0 were considered
positive and taken through to sequencing. Samples from
2007 were processed as described in Berkley et al., [27].
In this case, RNA was extracted from 200 ul of nasal
sample using the Magnapure LC Total Nucleic Acid
Isolation Kit (Roche, Manheim, Germany) and virus
detection conducted using the LightCycler Fast Start
DNA MasterPLUS Hyb-Probe kit (Roche, Mannheim,
Germany).
Gene specific PCR and sequencing
Surface proteins encoding genes, the fusion protein (F)
and glycoprotein (G), were amplified in a one-step RT-
PCR assay using Quantifast one-step RT-PCR system
(Qiagen, Valencia, CA, USA). Primers targeting the ecto-
domain region of the F protein to give a 405 bp product
were used to amplify a portion of the F gene as previ-
ously described [45]. Amplification of the G gene was
performed using semi-nested PCR to yield a 930 bp
product that included the G gene and a portion of the L
gene [7]. Amplified products of both the F and G gene
were checked on a 2 % agarose gel with Ethidium Bromide
staining to ascertain successful amplification. The remain-
der of the PCR products were purified using GFX DNA
purification kit (GFX-Amersham, Amersham, UK) accord-
ing to the manufacturer’s instructions and taken forward
for DNA sequencing. Because of PCR failures at the amp-
lification stage, only 130 and 98 samples (out of the total
of 160) were followed through to sequencing for F and G
gene, respectively. Purified PCR products were sequenced
using Big Dye Terminator 3.1 (Applied Biosystems, Foster
City, California, USA) using the same PCR primers in
both forward and reverse direction and generated with an
ABI Prism 3130xl Genetic Analyzer (Applied Biosystems,
Foster City, California, USA).
Sequence alignment, phylogenetic and molecular analysis
Raw sequences were assembled using either DNASTAR
or Sequencher (version 4.10.1, Gene Codes Corporation,
Ann Arbor, USA). Multiple sequence alignments (MSA)
were undertaken in MAFFT v7.220 [46]. G gene se-
quences were trimmed to approximately 606 bp to remove
the intergenic region and a portion of the L gene. To ob-
tain comparison data, a GenBank search was conducted
on 11-Jun-2015. The search terms were “human Metap-
neumovirus AND (F OR Fusion) AND 340[SLEN]:14000
[SLEN]” for F protein data, and “human metapneumo-
virus attachment AND 600[SLEN]:14000[SLEN]” for G
protein data. To be included in our comparison dataset
the sequences had to have a complete overlap in their
sequenced portion with Kilifi virus data, information on
the country sampled and sampling date (at least year) of
between 2007 and 2011. With these criteria we identi-
fied 290 (for F) and 233 (for G) sequences. Duplicate
sequences were dropped. Genbank accession numbers
of sequences for these analyses are available in Additional
file 1: Table S1 for F gene and Table S2 for G gene.
Phylogenetic trees were generated using both Max-
imum Likelihood (ML) and Bayesian methods: For ML
in MEGA v5.2.2 and for Bayesian in BEAST (Bayesian
evolutionary analysis and sampling of Trees) v1.8.2. To
genotype the Kilifi viruses, the F protein sequence data
were analyzed with reference sequences deposited in
GenBank (details provided in Additional file 1: Table
S1). A genotype was only confirmed if sequences clus-
tered with the reference sequences within a major
branch with >70 % bootstrap support on the ML tree.
Temporally structured phylogenetic trees were generated
using BEAST. Tip dates (dd-MMM-yyyy) were used in
all analyses. For comparison dataset sequences that had
only the year of collection, date of collection was esti-
mated to 01st of July of the reported year. All Bayesian
analyses used HKY, gamma distribution with invariant
sites as the model of evolution and demographic model
of constant population size. The analysis was set to 50
million steps sampling after every 2500 steps. The out-
put was only further analyzed when ESS (estimated sam-
ple size) for all parameters exceeded 200. We settled on
the above parameters in the Bayesian analyses after alter-
native more complex models e.g. general-time reversible
(GTR) failed to give a converged result. Maximum clade
credibility trees were calculated using Tree Annotator
1.8.2. and visualized in Fig Tree v1.4.2.
To analyze variation in sequences, unique sequences
and variable nucleotide and amino acid positions were
identified using in-house python and ruby scripts. Patristic
distances were analyzed in MEGA v5.2.2 [47]. Sequences
generated in this study are deposited in GenBank under
the accession numbers: KT191355-KT191484 for F and
KT191299-KT191354 for G protein.
Results
Study population
Between January 2007 and December 2011, there were
16,439 admissions to KCH aged between 1 day and
59 months, of which 32.1 % (5284) were eligible for
study as cases with syndromic severe or very severe
pneumonia (Table 1). Overall, 62.8 % of these children
were tested for HMPV, ranging by year between 43 and
83 % due to changes in proportion of non-residents of
KHDSS included in the different samples (15.4 % in
years 2007–09, versus 47.3 % in years 2010–11).
HMPV prevalence in child admissions
HMPV was detected in 160 (4.8 %) of the 3320 samples
tested. Prevalence by year ranged from 2.9 % in 2007 to
8.8 % in 2009 (Table 1). Almost half of HMPV positive
samples were identified in the years 2008 and 2009.
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Children under 6 months of age accounted for 44 % of
cases (71/160) while 74 % (118/160) of cases were in
children under 1 year old with only 1.3 % (2/160) HMPV
positive for children >36 months (Table 2). Of the 160
HMPV positive cases, 83.8 % (134/160) and 16.2 % (26/
160) presented with symptoms classified as either severe
or very severe pneumonia, respectively (Table 2).
Temporal occurrence and circulation patterns of HMPV
HMPV occurrence showed a seasonal pattern with the
majority of cases being detected in the period from
October of 1 year through to April of the next (Fig. 1a).
The seasonal increase in cases tended to coincide with
lower rainfall, higher temperature and lower relative
humidity (Fig. 1b). For subsequent analysis we assume
August as the end month of one season and September
the start of the next (hence the colour scheme in Fig. 1a).
However, there was no clear-cut demarcation between the
end of one seasonal epidemic and the next as sporadic
HMPV cases were detected in seasonal troughs, except for
the inter-epidemic period between the end of the 2009-10
and rise of the 2010-11 seasons, where no cases were ob-
served over a 6 month interval (Fig. 1a).
Genetic diversity of HMPV samples from KCH
PCR amplification of the F gene was more successful
than for the G gene, with 130 and 98 positive PCRs for F
and G gene, respectively. A total of 123 samples from the
160 HMPV positives were successfully sequenced for both
or either G or F gene only and genotyped (Table 1). There
was no statistically significant difference (P = 0.613) in Ct
values between sequenced samples and those that failed to
be sequenced (numbering 37).
Among the 123 samples successfully sequenced for the
F protein over a 345 nucleotide length region, 49 of these
were unique. Overall mean nucleotide diversity for this
subset was 0.106. In the phylogenetic analysis we combined
the Kilifi unique F sequences with all others deposited in
Genbank that were contemporaneous and overlapping in
the sequence F portion. Both A and B HMPV groups, spe-
cifically A2, B1 and B2 were observed in Kilifi (Fig. 2). Sub-
group A1 was not observed in Kilifi (Fig. 2). Within the
subgroups, virus sequences from the same epidemic did
not necessarily group together into marked clusters instead
they were interspersed on the phylogenetic tree with the
international sequences (Fig. 2). Majority of Kilifi se-
quences in the A2 subgroup occurred within three distin-
guishable clusters and when compared to global sequences,
clustered closely with sequences from Canada and Nairobi
Kenya and were highly similar in each of the subgroups in
which they fell (Fig. 2). A ML phylogeny of the HMPV F
sequences from Kilifi alone, color coded by epidemic is
given in Additional file 2: Figure S1A. Notably, phylogen-
etic clusters formed within the different subgroups on this
tree had sequences from multiple epidemic periods i.e. no
clear temporal clustering.
Table 1 Study population at Kilifi County Hospital, number tested and number of HMPV positive samples recorded
Number of children HMPV positive samples and genotypes
Year Admissions Eligible Tested (%) Number positive (%) a Genotyped (%) b A2 B1 B2
2007 3506 1174 726 (61.8) 21 (2.89) 10 (48) 4 2 4
2008 3204 1009 435 (43.1) 34 (7.82) 29 (85) 21 2 6
2009 3633 1105 526 (47.6) 46 (8.75) 35 (76) 26 0 9
2010 3091 1090 903 (82.8) 27 (2.99) 23 (85) 20 0 3
2011 3005 906 730 (80.6) 32 (4.38) 26 (81) 20 0 6
Total 16,439 5284 3320 (62.8) 160 (4.82) 123 (77) 91 4 28
a% number positive/tested
b% genotyped/number positive
Table 2 HMPV positives stratified by age group of patients and
pneumonia status in Kilifi County Hospital
Age group
(months)
Eligible Tested HMPV
positive
(%) a
Genotype
A2 (%) b B1 B2
0–2 1479 901 29 (18.1) 12 (9.8) 2 5
3–5 778 524 42 (26.3) 24 (19.5) 1 6
6–11 1143 703 47 (29.4) 32 (26.0) 0 5
12–23 1056 682 25 (15.6) 12 (9.8) 1 9
24–35 440 269 15 (9.4) 10 (8.1) 0 2
36+ 388 241 2 (1.3) 1 (0.81) 0 1
Total 5284 3320 160 (4.82) 91 (74) 4 28
Admission
condition
Severe
pneumonia
3783 2482 134 73 4 23
Very severe
pneumonia
1501 838 26 18 0 5
All pneumonia
(severe and
very severe)
5284 3320 160 91 4 28
a% HMPV positive/total HMPV positive; b( ) proportion of sequenced samples
(genotype/total genotyped)
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Of the 98 PCR positives for the G protein, 56 samples
sequenced successfully over the 606 nucleotides of the
HMPV G coding region. This represented coverage of
88.2 % of the entire G coding sequence. All the 56 se-
quences were determined to be of genotype A2 within
group A (figure not shown) with 53 providing unique se-
quences over the sequenced region. This unique subset
showed an overall mean genetic diversity of 0.079. An
ML phylogeny of the HMPV G sequences from Kilifi
alone, color coded by epidemic is given in Additional
file 2: Figure S1B.
The phylogenetic resolution was far greater with G
sequences compared to F sequences (Additional file 2:
Figure S1A), showing higher bootstrap support values
and longer branch lengths. Viruses deemed identical in
the F portion we sequenced possessed multiple nucleotide
differences in the G portion (Additional file 2: Figure
S1B). However, similar to what was observed in the F-
based phylogeny, Kilifi sequences did not cluster strictly
according to epidemic, but rather sequences from multiple
epidemic periods frequently occurred within the phylo-
genetic clusters but these tended to be those deriving from
successive epidemics (Additional file 2: Figure S1B).
Comparison of Kilifi G gene sequences with global
sequences showed that Kilifi sequences clustered closely
with some sequences from Canada, Peru, China and India.
However, there were clusters of sequences from Peru,
Canada, India, Greece, Uruguay and Rwanda for which close
relatives were absent in Kilifi (Fig. 3a). The Kilifi G se-
quences diverged into three major clusters (cluster 1, 2, 3 in
Fig 3; Additional file 2: Figure S1B) and one minor cluster (4
in Fig. 3). Each cluster consisted of sequences from viruses
from more than one epidemic; cluster 1 of epidemic 2010-
11; cluster 2 of epidemics 2008-09, 2009-10 and 2011-12
and cluster 3 of epidemics 2007-08, 2008-09, 2009-10 and
2010-11. Within each cluster, sequences from the same epi-
demic grouped together. While cluster 1 was distinctly re-
moved from the other clusters (Fig. 3) and majority of
global sequences, it was closely related to sequences mainly
from Asia specifically China and India. The major cluster of
Kilifi sequences (cluster 2) consisting of 22 sequences was
most closely related to one sequence from India. Sequences
in cluster 3 were closely related to sequences mainly from
Canada and a few sequences from India (Fig. 3). There was
a unique branch of sequences mainly from Peru and one
from China into which none of the Kilifi sequences fitted.
A temporal analysis of genotype occurrence and circula-
tion in Kilifi showed that the majority (91/123) of circulating
isolates were A2 and this type was dominant and circulating
in each of the five epidemics (Additional file 3: Figure S2)
while B1 (3.3 %, 4/123) and B2 (22.8 %, 28/123) occurred
less frequently (Table 1; Additional file 3: Figure S2).
Fig. 1 a Temporal distribution of HMPV positive samples in Kilifi over five years, showing number of positive samples each month on the primary
axis and number of samples tested monthly on the secondary axis. Different colours indicate the different epidemics the samples were assigned;
b Monthly weather patterns in Kilifi, Kenya in the period 2007–2011
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Whereas A2 and B2 were recorded in every epidemic and
two subgroups circulated concurrently in each epidemic, B1
was only present in epidemic 2007–2008 (Additional file 3:
Figure S2).
Subgroup prevalence patterns in Kilifi versus global
We compared the subgroup prevalence in the 123 F
sequences from Kilifi with 290 global sequences we
collated from GenBank to show genotype distribution by
year. The global dataset was drawn from seven
countries: Japan, Peru, Rwanda, Egypt, Thailand, India
and Canada. The patterns in Kilifi appeared considerably
distinct from the overall global patterns (Fig. 4). Only
the year 2010 in Kilifi mirrored genotypes trends that
were observed globally, with subgroup A2 dominating
(Fig. 4b).
Evolutionary analysis
We estimated the overall evolutionary rate for the F re-
gion analysed from the combined Kilifi-global sequence
Fig. 2 Phylogenetic relatedness and temporal divergence of the combined Kilifi and contemporaneous global F protein sequences over the
345-nucleotide portion analyzed. Taxa of Kilifi viruses are coloured red. Node bars indicate the 95 % HPD height interval of the nodes; the node
makers size are scaled by posterior support, for Kilifi, coastal Kenya 2007–11
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dataset. It was determined as 1.96 × 10−3 substitutions/
site/year (95 % HPD Interval: 1.37 × 10−3, 2.57 × 10−3).
This is including all group A and B strains. Divergence
dates of the groups A-B, subgroups A1-A2, and sub-
group B1-B2 from these F data were estimated as,
1944.16 [95 % HPD interval 1893.4, 1979.0], 1994.0
[95 % HPD interval 1986.3, 1998.9] and 1988.9 [95 %
HPD interval 1972.8, 1997.8], respectively (Fig. 2). A
similar analysis determined the evolutionary rate in the
G region we sequenced for the A2 genotype to be
5.915 × 10−3 substitutions/site/year (95 % HPD Interval:
4.147 × 10−3, 7.887 × 10−3).
Analysis of protein changes in the F and G genes
The HMPV G protein is on average 236 amino acids
long. For the Kilifi genotype A2 G protein sequences
were predicted to encode 3 different protein lengths:
213, 217 or 228 due to usage of alternative stop codons.
Our sequencing of the subgroup A2 was from amino
acid 28 to end. We observed changes in these sequences
leading to gains or loss of N-glycosylation sites. A total
of five N-glycosylation sites at positions 30, 52, 145, 152
and 180 were identified on the sequenced G protein.
One-hundred-three of the 228 codon positions were
polymorphic and up to 5 variants were identified based
on sharing a combination of ≥5 signature amino acid
residues. There were six sites where amino acid changes
led to gain and another eight different sites where changes
led to loss of N-glycosylation (Additional file 4: Figure
S3). The frequency of gain and loss of N-glycosylation
overall was 36 and 56, respectively. Position 180 had
one of the most frequent losses in N-glycosylation
that occurred in 39 sequences. Overall, from the
amino acid changes observed, the pattern of changes
clearly demarcated the sequence set into five clusters
(Additional file 4: Figure S3).
Fig. 3 Phylogenetic and temporal placement of Kilifi group A G protein sequenced viruses, for Kilifi, coastal Kenya 2007–2011. Panel a A total of
209 viruses compared in G sequences G (53 from Kilifi and 156 collated from GenBank from 7 countries). Branches leading to Kilifi viruses are
coloured red. Three letter codes of countries comprising branches without Kilifi representative sequences are indicated next to the vertical line.
Panel b 121 viruses that fell within the ancestral node leading to Kilifi viruses were reanalyzed in BEAST. Again branches and leaves of Kilifi viruses
are colored red on the phylogenetic temporally calibrated tree. Node bars indicate the 95 % HPD height interval of the nodes; the node maker
sizes are scaled by posterior support. The number 1, 2, 3 and 4 represent the three major and one minor cluster of sequences from Kilifi
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The HMPV F protein is on average 539 amino acids
long. Our F sequencing encompassed 105 codon posi-
tions, representing 19.5 % of the entire F protein se-
quence. Of those that we sequenced, 15 % (17/115)
showed amino acid changes, confirming its high degree
of conservation. There was no N-glycosylation site
observed in the sequenced region of the F protein
(Additional file 5: Figure S4).
Discussion
The epidemiological and evolutionary patterns of circu-
lating strains of HMPV remains poorly documented in
most of sub-Saharan Africa. Using an existing frame-
work for childhood pneumonia surveillance at a referral
hospital in coastal Kenya we set out to describe HMPV
epidemiology as well as its genetic diversity in this re-
gion and compared findings to global contemporaneous
strains deposited into GenBank.
We found that 4.8 % of childhood pneumonia hospital
admissions for the period 2007 to 2011 (inclusive) in
Kilifi County Hospital were HMPV positive. Our results
fall in the range 3.8 to 15 % [13–15, 20, 23, 48] reported
in pediatric hospital admissions in other parts of the
world. A previous study in Kenya (albeit in a refugee
population) identified HMPV prevalence of 5.7 % [17].
The HMPV infections in KCH admissions were most
common in children <6 months (44 %), and 74 % of all
HMPV cases occurred in children under 12 months of
age, with 84 % of cases presenting with symptoms of se-
vere pneumonia. Substantial disease burden associated
with HMPV in the first year of life has been previously
reported [7, 13, 16, 22, 49], highlighting the most affected
age group and providing a guide on the populations to
prioritize in future HMPV vaccine administration.
A seasonal pattern to HPMV positive samples was
identified from October of 1 year to April of the next,
corresponding to higher temperatures and lower rainfall.
This is similar to the seasonal pattern of RSV at the
same site [49, 50]. In Dadaab, a refugee camp 500Km
north of Kilifi, peak HMPV prevalence occurs in Decem-
ber [17], similar to Kilifi. In other parts of the world, sea-
sonality in HMPV prevalence has been previously
reported [14, 15, 17] with peak prevalence either coin-
ciding with the winter season, concurrent or after the
RSV epidemic season [13, 15, 20]; alternating between
winter and spring [51] or peaking in the late spring-
summer months [52] in the northern hemisphere whilst
studies in Australia show peak seasons in spring [16]
which is concurrent with the RSV peak season. In 2010,
no HMPV was detected between April and September.
Studies in Europe have similarly shown HMPV preva-
lence varies from year to year [51, 52].
Three HMPV subgroups A2, B1, B2 were found in Kilifi
during the study period; A1 was absent but A2 and B2 oc-
curred over the whole surveillance period whilst B1 was
only recorded in the 2007 and 2008 in low numbers. All
the samples sequenced for G gene were A2, reflecting the
fact that A2 was the predominant subtype in Kilifi in every
season/year of the study. Examination of global HMPV se-
quences in GenBank for the period covered in our study
showed low representation of A1, possibly explaining its ab-
sence from Kilifi. Interestingly, studies have shown A1 to
be dominant in the USA [13] and South Africa [25] and B1
in an Australian study of inpatient admissions of all ages
over a 4 year period [16]. Genotype B1 was only detected in
2007 and 2008, and undetectable in the remaining 3 years.
Our analysis of comparison sequence data in public data-
bases of the same period showed that B1 was indeed
Fig. 4 Pie charts showing the genotype distribution by year derived from F sequence analysis of samples from Kilifi, Coastal Kenya 2007-11. Panel
a This is based on the 290 F sequences collated from GenBank. Panel b This is based on 123 F sequences generated from samples that were collected
in this study at the KCH between 2007 and 2011. The numbers inside the pies indicate the genotype proportions per the respective year
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circulating elsewhere in the 3 years that we did not detect it
in Kilifi. A 20-year study in the USA reported sporadic de-
tection of B1 genotype [53] and may in part explain the
intermittent pattern of occurrence that we observe in Kilifi.
Studies covering a longer time period may better resolve
the pattern of genotype occurrence. The identification of
three subgroups of HMPV was possible using only F se-
quence data and not the G sequence data possibly owing to
the larger number of samples successfully sequenced for
the F.
Co-circulation of multiple lineages of HMPV has been
previously reported [7, 14, 53, 54]. Furthermore, domin-
ant strains may vary in different seasons and locations
[7, 36, 55] and genotypes may dominate in 1 year then
be replaced by another the subsequent year [16, 30, 53].
In Kilifi, our data showed a contrasting scenario with
one subgroup A2 dominant in all seasons, with the other
subgroups especially B2 co-circulating in lower numbers.
Long-term surveillance to ascertain if there is genotype
replacement in the subsequent years after the study will
be important in determining genotype patterns in Kilifi.
The dissimilarity between the distribution of genotypes
in circulation in Kilifi relative to the global pattern, com-
paring year by year, supports the hypothesis that HMPV
migrates across the world at a relatively slower rate
compared to other respiratory viruses like Influenza A
to allow the existence of localized genotype replacement
patterns.
The G gene is the most variable gene in the HMPV
genome [10, 56]. It has been suggested that frequent
variation in the G gene may be a strategy to evade the
host immune system selective pressure [57]. We found
that the G protein evolutionary rate was three times
higher in the region we analyzed compared to the F pro-
tein evolutionary rate. Overall the diversity observed in
the G protein sequences was far higher as compared to
the F protein sequences. Although the all G sequences
we obtained were of A2 subgroup, based on the phylo-
genetic clustering, bootstrap support and amino acid
change patterns, we could classify our A2 subgroup vi-
ruses into four further clusters.
Amplification and sequencing of the G protein did not
succeed for more than half of our HMPV positive samples.
About 60 samples failed at the G PCR amplification stage
and a further 30 failed at the nucleotide sequencing stage.
In the end we only obtained sequences for subgroup A2. It
is possible that this was caused by insufficient match of our
primers to the circulating variants/subgroups thus imped-
ing amplification and sequencing. This low recovery rate of
the HMPV G protein sequences limited our study power
to fully understand genotypes and variants that circulated
in Kilifi over the study period. An alternative explanation
for the PCR/sequencing failures is possible RNA deg-
radation as the study used archived material.
The HMPV F gene was determined to be less diverse
which concurs with previous findings and pneumovirus
F protein diversity in general [8]. Furthermore, 52 % (64/
123) of the F gene sequences were determined as 100 %
identical to a sequences in the remaining set whilst only
5.3 % (3/56) of the G gene sequences were identical to
each other. This suggests that to tease out any differences
between these sequences that are 100 % F gene identical,
sequencing another gene for instance the G gene or even
the whole genome will be necessary.
Whilst there were no N-glycosylation sites detected in
the F protein sequenced and only few amino acid
changes observed, the G protein had more sites where
there was loss of N-glycosylation and also had several
amino acid changes owing to the more nucleotide se-
quence diversity observed. The F portion we sequenced
does not encompass the three potential N-glycosylation
sites at positions 57, 127 and 353 that have been previ-
ously described for HMPV [58].
Many of the characteristic epidemiological and evolu-
tionary patterns observed in this study for HMPV mirror
the findings previously reported for RSV from the Kilifi
population. For both viruses, the highest disease burden
is in the paediatric population occurring during early in-
fancy (though HMPV burden is overall smaller) [49].
Both RSV and HMPV show an annual seasonal pattern
with peak activity months well overlapped [49, 50] and
multiple genotypes occur during epidemics [50, 59]. Fur-
ther we show that like for RSV, analysis of the G protein
encoding region distinguishes better the variability of
strains occurring across epidemics than the F [60].
Nonetheless, a few differences can still be picked in their
patterns. Firstly, group/subgroup temporal dominance
or replacement is clearer with RSV than HMPV [59].
Secondly, the substitution rate observed in HMPV G
appeared much higher than estimated for RSV G [61].
Thirdly, most of the genetic variants in RSV occur over
a single epidemic and disappear but for HMPV, variants
seem to persist for more than a single epidemic before
disappearing [50]. To provide further new insights, fu-
ture studies should undertake whole genome study of
these viruses and analyze specimens collected over a
longer time period and across multiple sites in Kenya
and Africa for a better understanding of the transmis-
sion, evolution and persistence mechanisms of these im-
portant human pathogens.
There are a number of limitations of this study that
should be considered when interpreting the results.
Fewer G gene sequences were obtained from the study,
relative to F, and this could be the reason that only the
A2 variant from the worldwide pool was identified.
There was a change through time in the selection of
samples for testing based on residency status, which
would have resulted in a wider catchment area for 2010-
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11 than earlier. However, the low level of temporal clus-
tering observed suggests the samples to be drawn from a
similar pool of variants. As noted in previous reports
from this surveillance [27, 43, 49], collection of nasal
specimens from children with life-threatening features is
a continual challenge that could bias estimates of preva-
lence and variant composition.
Conclusions
In conclusion, we report on 5 years of epidemiological sur-
veillance and on circulating HMPV genotypes in the coastal
Kenyan location of Kilifi. The study reveals three of the four
globally circulating HMPV subgroups, with the same dom-
inance of A2 subgroup, but with annual variation in sub-
group prevalence not mirrored in the wider global dataset,
and little temporal clustering of the subgroups A2 in this
region of the world. The dissimilarity between the distribu-
tion of genotypes in circulation in Kilifi relative to the glo-
bal pattern, may suggest that slow global migration of
HMPV allows the existence of localized genotype replace-
ment patterns. One major peak season of HMPV was ob-
served, and prevalence was universally highest in infants,
especially those <6 months of age. Furthermore, HMPV
cases occurred in roughly annual outbreaks, with a preva-
lence of around 5 % in severe and very severe pneumonia
paediatric admissions to the County hospital.
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